Through statistical analysis of all variations, in NSCLC patients with PALB2gmut, the most frequently mutated gene was TP53 (65%), followed by CYP2C19 (51%), DPYD (45%), RAC1 (45%), VEGFA (44%), EGFR (43%), MGMT (42%), and CD74 (40%) (Figure 2A); the mutation frequency of TP53 was the highest in NSCLC with PALB2smut (64%), followed by CYP2C19 (47%), UGT1A1 (38%), RAC1 (36%), VEGFA (36%), CD74 (36%), EGFR (30%), and LRP1B (30%) (Figure 2B). This evidence concerns the gene RAC1 and non-small cell lung carcinoma.